Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer.

ABSTRACT:

Purpose

Existing cell-free DNA (cfDNA) methods lack the sensitivity needed for detecting minimal residual disease (MRD) following therapy. We developed a test for tracking hundreds of patient-specific mutations to detect MRD with a 1,000-fold lower error rate than conventional sequencing.

Experimental design

We compared the sensitivity of our approach to digital droplet PCR (ddPCR) in a dilution series, then retrospectively identified two cohorts of patients who had undergone prospective plasma sampling and clinical data collection: 16 patients with ER+/HER2- metastatic breast cancer (MBC) sampled within 6 months following metastatic diagnosis and 142 patients with stage 0 to III breast cancer who received curative-intent treatment with most sampled at surgery and 1 year pos

SUBMITTER: Parsons HA 

PROVIDER: S-EPMC7654718 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature